Back to search
FDAFDA · Food and drugs·Recall number D-0649-2021

Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03

Published July 14, 2021 · Recall initiated: February 26, 2021

Summary

FDA records drug Class II recall D-0649-2021, published July 14, 2021 and initiated February 26, 2021. Recalling firm: Alvogen, Inc; Status: Terminated; Reported quantity: 9,696 cartons; Lot: Lot #: 36924, Exp 6/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPRENORPHINE AND NALOXONE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPRENORPHINE AND NALOXONE
Manufacturer
Alvogen, Inc
Distributor
USA nationwide.
UPC
0347781356118
Lot
Lot #: 36924, Exp 6/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03 recalled?

Yes. FDA published recall D-0649-2021 on July 14, 2021. Reported hazard: Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPRENORPHINE AND NALOXONE. UPC: 0347781356118.